IL-28B rs12979860位点与乙肝病毒感染后自发清除及干扰素治疗应答关系的Meta分析

于风雪; 姜乐; 马宁; 张晓琳; 权媛; 刘殿武

doi:10.16462/j.cnki.zhjbkz.2016.07.016

IL-28B rs12979860位点与乙肝病毒感染后自发清除及干扰素治疗应答关系的Meta分析

doi: 10.16462/j.cnki.zhjbkz.2016.07.016

于风雪¹,
姜乐¹,
马宁²,
张晓琳²,
权媛³,
刘殿武^2, ,

1. 河北医科大学第二医院科研处, 河北石家庄 050000;
2. 河北医科大学流行病学教研室, 河北石家庄 050017;
3. 河北省胸科医院结核科, 河北石家庄 050041

基金项目:

国家自然科学基金青年科学基金（81402729）；河北省自然科学基金（H2015206152）；河北省科技厅课题（13277732D）

详细信息

作者简介:
于风雪(1974-),女,河北保定人,副研究员,博士。主要研究方向:肝病分子流行病学。

中图分类号: R512.62
计量
- 文章访问数: 286
- HTML全文浏览量: 58
- PDF下载量: 25
- 被引次数: 0
出版历程
- 收稿日期: 2016-01-15
- 修回日期: 2016-04-20

Association of IL-28B rs12979860 with spontaneous HBV clearance and interferon treatment response: a Meta-analysis

1. Department of Science and Technology, the Second Hospital of Hebei Medical University, Shijiazhuang 050000, China;
2. Department of Epidemiology, Hebei Medical University, Shijiazhuang 050017, China;
3. Department of Tuberculosis, the Chest Hospital of Hebei Province, Shijiazhuang 050041, China

摘要

摘要: 目的探索白细胞介素28B（interleukin- 28B，IL-28B）基因rs12979860位点与乙型肝炎病毒（hepatitis B virus，HBV）感染后自发清除及干扰素治疗应答的关系。方法检索2010年1月1日～2015年8月31日PubMed、Embase、中文科技期刊全文数据库、万方数据库、中国生物医学文献数据库、中国期刊全文数据库公开发表文献，对符合纳入和排除标准文献提取数据后采用Stata 12.0 软件进行Meta分析。结果共纳入12篇文献，根据研究目的分为两组：A组为HBV自发清除组和持续感染组，共5篇文献；B组：干扰素治疗应答组和非应答组，共9篇文献。Meta分析结果：rs12979860位点与HBV感染后自发清除无关联（OR=0.96，95% CI：0.76～1.20，P=0.700）；rs12979860位点与乙型肝炎e抗原阳性慢性HBV感染后干扰素治疗应答无关联（OR=0.93,95% CI：0.43～2.00，P=0.848），而突变基因型TC+TT 降低了乙型肝炎e抗原阴性慢性HBV感染后干扰素治疗应答（OR=0.47,95% CI：0.25～0.87，P=0.016）。结论 IL-28B基因的rs12979860位点突变基因型TC+TT降低了乙型肝炎e抗原阴性慢性HBV感染后干扰素治疗的应答。
- 基因 /
- 肝炎, 乙型, 慢性 /
- Meta分析
Abstract: Objective To investigate the association of SNP-rs12979860 in Interleukin- 28B (IL-28B) gene with spontaneous Hepatitis B Virus (HBV)clearance and interferon treatment response in patients with chronic hepatitis B. Methods Data published from January 1, 2010 to August 31, 2015 were retrieved from PubMed,Embase,CNKI,Wan-fang database,VIP database and CBM disc. The meta-analysis was performed to analyze the data. Results Twelve papers were obtained and were divided into two groups according to the purpose of the study. Group A included five articles about rs12979860 and spontaneous HBV clearance, and group B included nine articles about rs12979860 and interferon treatment response. The meta-analysis showed that there was no association between rs12979860 and spontaneous HBV clearance (OR=0.96,95% CI:0.76-1.20,P=0.700) and the response after interferon treatment for HBeAg-positive patients (OR=0.93, 95% CI:0.43-2.00,P=0.848), respectively. There was positive correlation between rs12979860 and the response after interferon treatment for HBe-negative patients, which manifested that the mutant genotype TC+TT significantly reduced the response after interferon treatment for HB e-negative patients. (total OR=0.47, 95% CI:0.25-0.87,P=0.016). Conclusions The mutant genotype TC+TT located on rs12979860 from gene IL-28B reduced the response after the interferon treatment for HBe-negative patients.
- Genes /
- Hepatitis B, chronic /
- Meta-analysis

HTML全文

参考文献(31)

Hou J, Liu Z, Gu F. Epidemiology and Prevention of Hepatitis B Virus Infection [J]. Int J Med Sci, 2005, 2(1):50-57.

Liaw YF, Chu CM. Hepatitis B virus infection [J]. Lancet, 2009, 373(9663): 582-592.

Liaw YF. Hepatitis B virus replication and liver disease progression: the impact of antiviral therapy [J]. Antivir Ther, 2006,11(6):669-679.

Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues [J]. Gastroenterology, 2009,137(5):1593-1608 .

Tseng LH, Lin MT, Shau WY, et al. Correlation of interleukin-10 gene haplotype with hepatocellular carcinoma in Taiwan [J]. Tissue Antigens, 2006,67(2):127-133.

Kim YJ, Lee HS, Yoon JH, et al. Association of TNF-alpha promoter polymorphisms with the clearance of hepatitis B virus infection [J]. Hum Mol Genet, 2003,12(19):2541-2546.

Dakin H, Fidler C, Harper C. Mixed treatment comparison meta-analysis evaluating the relative efficacy of nucleos(t)ides for treatment of nucleos(t)ide-naive patients with chronic hepatitis B [J]. Value Health, 2010,13(8):934-945.

Gish RG. Current treatment and future directions in the management of chronic hepatitis B viral infection [J]. Clin Liver Dis, 2005,9(4):541-565.

Tanaka Y, Nishida N, Sugiyama M, et al. Genome-wide association of IL-28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C [J]. Nat Genet, 2009, 41(10):1105-1109.

Ge D, Fellay J, Thompson AJ, et al. Genetic variation in IL-28B predicts hepatitis C treatment-induced viral clearance [J]. Nature, 2009,461(7262):399-401.

Rauch A, Kutalik Z, Descombes P, et al. Genetic variation in IL-28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study [J]. Gastroenterology, 2010,138(4):1338-1345.

Suppiah V, Moldovan M, Ahlenstiel G, et al. IL-28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy [J]. Nat Genet, 2009,41(10):1100-1104.

Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL-28B and spontaneous clearance of hepatitis C virus [J]. Nature, 2009,461(7265):798-801.

Martin MP, Qi Y, Goedert JJ, et al. IL-28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection [J]. J Infect Dis, 2010,202(11):1749-1753.

Martin-Carbonero L, Rallon NI, Benito JM, et al. Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B? [J]. AIDS Res Hum Retroviruses, 2012,28(10):1262-1264.

Ren S, Lu J, Du X, et al. Genetic variation in IL-28B is associated with the development of hepatitis B-related hepatocellular carcinoma [J]. Cancer Immunol Immunother, 2012,61(9): 1433-1439.

Peng LJ, Guo JS, Zhang Z, et al. IL-28B rs12979860 polymorphism does not influence outcomes of hepatitis B virus infection [J]. Tissue Antigens, 2012,79(4):302-305.

Li W, Jiang Y, Jin Q, et al. Expression and gene polymorphisms of interleukin 28B and hepatitis B virus infection in a Chinese Han population [J]. Liver Int, 2011,31(8):1118-1126.

Holmes JA, Nguyen T, Ratnam D, et al. IL-28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha [J]. J Gastroenterol Hepatol, 2013,28(5):861-866.

Sonneveld MJ, Wong VW, Woltman AM, et al. Polymorphisms near IL-28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B [J]. Gastroenterology, 2012, 142(3):513-520.

Lampertico P, Vigano M, Cheroni C, et al. IL-28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B [J]. Hepatology, 2013,57(3):890-896.

de Niet A, Takkenberg RB, Benayed R, et al. Genetic variation in IL-28B and treatment outcome in HBeAg-positive and -negative chronic hepatitis B patients treated with Peg interferon alfa-2a and adefovi [J]. Scand J Gastroenterol, 2012,47(4):475-481.

Chen CM, Zhou FY, Zhou YP, et al. Relationship between single nucleotide polymorphisms in IL-28B gene and response to interferon treatment in chronic hepatitis B patients [J]. Nan Fang Yi Ke Da Xue Xue Bao, 2011,31(12):2012-2015.

Wu H, Zhao G, Qian F, et al. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B [J]. Liver Int, 2015, 35(2): 473-481.

Cheng L, Sun X, Tan S, et al. Effect of HLA-DP and IL28B gene polymorphisms on response to interferon treatment in hepatitis B e-antigen seropositive chronic hepatitis B patients [J]. Hepatol Res, 2014, 44(9):1000-1007.

Kempuraj D, Donelan J, Frydas S, et al. Interleukin-28 and 29 (IL-28 and IL-29): new cytokines with anti-viral activities[J]. Int J Immunopathol Pharmacol, 2004,17(2):103-106.

Sheppard P, Kindsvogel W, Xu W, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R[J]. Nat Immunol 2003, 4(1): 63-68.

Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex[J]. Nat Immunol, 2003, 4(1): 69-77.

Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, et al. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C [J]. BMC Med, 2013,11:6.

Wu LS, Wang H, Geng XP. Two IL28B polymorphisms are associated with the treatment response of different genotypes of hepatitis C indifferent racial populations: a meta-analysis [J]. Exp Ther Med, 2012,3(2):200-206.

Li S, Hu P, Zhang QQ, et al. Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B[J]. Hepat Mon, 2011,11(3):163-172.

施引文献

资源附件(0)

访问统计